Zymeworks Inc ZYME
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-06-24 |
| Shares Out. | 71,590,000 |
| Website | zymeworks.com/ ↗ |
| Phone | 13022748744 |
| Employees | 264 |
| Revenue | $2.4M |
| Gross Profit | $2.4M |
| Net Income | -$44.2M |
| Free Cash Flow | -$77.0M |
| Total Assets | $478.2M |
| Total Liabilities | $314.6M |
| Equity | $163.6M |
About Zymeworks Inc
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks Inc is a publicly traded company under the ticker symbol ZYME on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)